Inovio Pharmaceuticals, Inc. (BMV:INO)
Mexico · Delayed Price · Currency is MXN 47.50
+0.50 (1.06%)
At close: Oct 9, 2025
Inovio Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Net Income | -87.76 | -107.25 | -135.12 | -279.82 | -303.66 | -167.47 | Upgrade |
Depreciation & Amortization | 3.03 | 3.13 | 3.5 | 5.5 | 4.73 | 4.63 | Upgrade |
Stock-Based Compensation | 4.79 | 6.6 | 11.07 | 22.56 | 26.34 | 15.65 | Upgrade |
Other Adjustments | -1.89 | -3.88 | 6.44 | 15.72 | 6.53 | 40.29 | Upgrade |
Change in Receivables | - | 1.21 | 9.33 | -3.71 | 11.03 | -17.02 | Upgrade |
Changes in Accounts Payable | -2.5 | -3.37 | -45.99 | 32.61 | 26.14 | 3.25 | Upgrade |
Changes in Accrued Expenses | -3.99 | -0.34 | -8.23 | 0.27 | 0.38 | 5.96 | Upgrade |
Changes in Unearned Revenue | - | - | - | -0.09 | -0.04 | -0.06 | Upgrade |
Changes in Other Operating Activities | -2.68 | -0.16 | 34.63 | -9.25 | 12.84 | -63.21 | Upgrade |
Operating Cash Flow | -94.79 | -104.08 | -124.37 | -216.22 | -215.71 | -177.98 | Upgrade |
Capital Expenditures | - | -0.49 | -0.32 | -0.97 | -1.23 | -1.52 | Upgrade |
Sale of Property, Plant & Equipment | - | 0.06 | 6.22 | - | - | - | Upgrade |
Purchases of Investments | -29.72 | -54.14 | -203.48 | -250.53 | -348.95 | -157.62 | Upgrade |
Proceeds from Sale of Investments | 83.71 | 158.64 | 284.93 | 361.08 | 174.84 | 103.12 | Upgrade |
Other Investing Activities | - | - | - | - | - | -2.77 | Upgrade |
Investing Cash Flow | 53.95 | 104.07 | 87.36 | 109.59 | -175.34 | -58.8 | Upgrade |
Long-Term Debt Repaid | - | -16.42 | - | - | - | - | Upgrade |
Net Long-Term Debt Issued (Repaid) | - | -16.42 | - | - | - | - | Upgrade |
Issuance of Common Stock | - | 68.31 | 5.46 | 83.24 | 216.11 | 466.76 | Upgrade |
Repurchase of Common Stock | - | -0.42 | -0.47 | -1.4 | -4.61 | -4.03 | Upgrade |
Net Common Stock Issued (Repurchased) | - | 67.89 | 5 | 81.84 | 211.5 | 462.73 | Upgrade |
Other Financing Activities | - | - | - | - | - | 2.55 | Upgrade |
Financing Cash Flow | 30.8 | 51.48 | 5 | 81.84 | 211.5 | 465.28 | Upgrade |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | 0.03 | -0 | -0.03 | -0.03 | 0.03 | Upgrade |
Net Cash Flow | -10.04 | 51.5 | -32.02 | -24.81 | -179.58 | 228.53 | Upgrade |
Beginning Cash & Cash Equivalents | 34.39 | 14.31 | 46.33 | 71.14 | 250.73 | 22.2 | Upgrade |
Ending Cash & Cash Equivalents | 24.35 | 65.81 | 14.31 | 46.33 | 71.14 | 250.73 | Upgrade |
Free Cash Flow | -94.79 | -104.56 | -124.69 | -217.18 | -216.94 | -179.5 | Upgrade |
FCF Margin | -51987.60% | -48019.06% | -14986.17% | -2116.34% | -12223.61% | -2422.00% | Upgrade |
Free Cash Flow Per Share | -2.80 | -3.85 | -5.62 | -10.92 | -12.47 | -13.89 | Upgrade |
Levered Free Cash Flow | -93.9 | -124.9 | -151.53 | -251.75 | -260.84 | -384.84 | Upgrade |
Unlevered Free Cash Flow | -101.99 | -113.63 | -160.35 | -239.51 | -258.4 | -175.03 | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.